Clinical Trial

68Ga-BCMA PET/CT in Multiple Myeloma

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography/computed tomography (PET/CT) in patients with multiple myeloma and related plasma cell disorders. The study aims to non-invasively visualize and quantify whole-body BCMA expression and to assess its role in the detection of active disease and disease heterogeneity.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-06-23
critical Primary endpoint(s) modified 2026-06-23
Trial Details
NCT Number NCT07319897
Lead Sponsor Peking University First Hospital
Collaborators: The First Hospital of Jilin University, The Second Hospital of Hebei Medical University, Beijing Anzhen Hospital, Beijing Tsinghua Changgeng Hospital
Conditions Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm
Enrollment 300 participants
Start Date 2025-12-25
Primary Completion 2027-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-22